Connect to other sites within the UBM Medica Network
High Variability in Diagnosis of Dense Breasts
A recent study found that radiologists differ in their interpretation of whether a woman has dense breasts based on mammography.
MRD Has Prognostic Value in Elderly Myeloma Patients
A new study found that monitoring of minimal residual disease in a group of elderly patients with multiple myeloma proved to have important prognostic value, regardless of patient age or cytogenetic risk.
MicroRNAs Could Help Predict Response to TKIs for Metastatic RCC
A new study has found a series of potential microRNA biomarkers that could predict tyrosine kinase inhibitor response in RCC patients.
ALK Mutation Variant May Affect Response to Targeted Agents
ALK-targeting agents such as crizotinib may work most effectively in lung cancer patients with ALK variant 1.
IVF Did Not Increase Breast Cancer Incidence
Results from a long-term study indicated that undergoing fertility treatment with in vitro fertilization did not increase women’s risk for breast cancer compared with women in the general population.
Frontline ATRA/Arsenic Trioxide Improves Survival in APL
The advantage of treating low- or intermediate-risk APL with ATRA plus arsenic trioxide appears to increase over time, according to results of the APL0406 trial.
Study Offers Limited Support for Mediterranean Diet’s Effect on Breast Cancer Incidence
A meta-analysis found that a Mediterranean diet with no limits on fat intake may reduce the incidence of breast cancer, as well as several other outcomes, compared to other diets.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
November 2015 News Roundup
In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
By clicking Accept, you agree to become a member of the UBM Medica Community.